Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 2570.

https://doi.org/10.1182/blood-2019-130898

Published: 2019

Journal Articles

A Network of Activated Cancer Signaling Pathways in a High Risk Subgroup of Acute Myeloid Leukemia Targetable By SRC-Kinase Inhibitors

Claudia Chiriches, PhD, Dilawar Khan, PhD, Nathalie Guillen, PhD, Michal Rokicki, Carol Guy, Afsar Mian, PhD, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2016) 128 (22): 2746.

https://doi.org/10.1182/blood.V128.22.2746.2746

Published: 2016

Journal Articles

Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL

Afsar Mian, PhD, Isabella Haberbosch, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2014) 124 (21): 4523.

https://doi.org/10.1182/blood.V124.21.4523.4523

Published: 2014

Journal Articles

Mechanisms of Antileukemic Activity of the Multikinase Inhibitors Dasatinib and Ponatinib in Acute Lymphoblastic Leukemia (ALL) Harboring the E2A-PBX1 Fusion Gene

Tamara Tesanovic, Susanne Badura, Thomas Oellerich, Claudia Doering, Martin Ruthardt, MD, Oliver G. Ottmann, MD

Blood (2014) 124 (21): 3595.

https://doi.org/10.1182/blood.V124.21.3595.3595

Published: 2014

Journal Articles

The GSK3β-Phosphorylation Sites in the DEK-Portion Are Indispensable for the Leukemogenic Potential of the DEK/CAN Fusion Protein in t(6;9)-Positive Acute Myeloid Leukemia

Claudia Oancea, PhD, Maria Heinßmann, Nathalie Guillen, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2014) 124 (21): 3574.

https://doi.org/10.1182/blood.V124.21.3574.3574

Published: 2014

Journal Articles

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome Positive Acute Lymphatic Leukemia

Afsar Mian, PhD, Anahita Rafiei, Claudia Oancea, PhD, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2014) 124 (21): 2402.

https://doi.org/10.1182/blood.V124.21.2402.2402

Published: 2014

Journal Articles

PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL

Afsar Mian, PhD, Anahita Rafiei, Anna Metodieva, Isabella Haberbosch, Alexey Zeifman, Ilya Titov, Victor Stroylov, Oleg Stroganov, Fedor Novikov, Oliver G. Ottmann, MD, Ghermes Chilov, Martin Ruthardt, MD

Blood (2013) 122 (21): 3907.

https://doi.org/10.1182/blood.V122.21.3907.3907

Published: 2013

Journal Articles

The Reciprocal t(9;22) p96 ABL/BCR fusion Protein Eenhances the Transformation Potential of BCR/ABL and Increases Therapy Resistance in Models of Ph+ Acute Lymphatic Leukemia

Anahita Rafiei, Afsar Mian, PhD, Anna Metodieva, Claudia Oancea, Hubert Serve, MD, Heike Pfeifer, MD, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2012) 120 (21): 3539.

https://doi.org/10.1182/blood.V120.21.3539.3539

Published: 2012

Journal Articles

The Activation of STAT3 and 5 in t(6;9)(DEK/CAN)-Positive Acute Myeloid Leukemia Models Is Inhibited by Exposure to Arsenic Trioxide

Claudia Oancea, Hannelore Held, Maria Heinssmann, Boris Brill, Hubert Serve, Prof. Dr. med., Martin Ruthardt, MD

Blood (2012) 120 (21): 1384.

https://doi.org/10.1182/blood.V120.21.1384.1384

Published: 2012

Journal Articles

T(6;9)-DEK/CAN-Positive Leukemia: Role of FLT3-ITD for the Determination of the Leukemic Phenotype

Maria Heinssmann, Lena Drangmeister, Katharina Schmid, Maren Keller, Hubert Serve, Prof. Dr. med., Claudia Oancea, Martin Ruthardt, MD, Gesine Bug

Blood (2012) 120 (21): 1316.

https://doi.org/10.1182/blood.V120.21.1316.1316

Published: 2012

Journal Articles

Enzymatically Inactive 5-Lipoxygenase Inhibits Wnt-Signaling Activation Induced by Leukemia Inducing Oncogenes.

Jessica Roos, Maria Heinßmann, Claudia Oancea, Thorsten Maier, Dieter Steinhilber, Hubert Serve, MD, Martin Ruthardt, MD

Blood (2012) 120 (21): 2424.

https://doi.org/10.1182/blood.V120.21.2424.2424

Published: 2012

Journal Articles

Modulation of Leukemic Stem Cell Self-Renewal and Cell Fate Decisions by Inhibition of Hedgehog Signalling in Human Acute Lymphoblastic Leukemia (ALL).

Fabian Lang, MD, Susanne Badura, Martin Ruthardt, MD, Michael A. Rieger, Oliver G. Ottmann, MD

Blood (2012) 120 (21): 2578.

https://doi.org/10.1182/blood.V120.21.2578.2578

Published: 2012

Journal Articles

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

Anna T. Metodieva, Heike Pfeifer, MD, Afsar Mian, PhD, Anja Vogel, Hubert Serve, Prof. Dr. med., Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2012) 120 (21): 2579.

https://doi.org/10.1182/blood.V120.21.2579.2579

Published: 2012

Journal Articles

Differential Suppressive Effects of Selective PI3K and mTOR and Dual PI3K/mTORC1/C2 Inhibition on Long-Term Cultured Primary Human Acute Lymphoblastic Leukemia (ALL) Cells Implicate a Distinct Role of mTORC2.

Susanne Badura, Tamara Tesanovic, Heike Pfeifer, MD, Catherine Hohnloser, Marcus Liebermann, Hubert Serve, MD, Martin Ruthardt, MD, Oliver G. Ottmann, MD

Blood (2010) 116 (21): 1032.

https://doi.org/10.1182/blood.V116.21.1032.1032

Published: 2010

Journal Articles

The Protein Tyrosine Phosphatase STS-1 Interacts with Bcr-Abl and Impairs the Response of Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) to Tyrosine Kinase Inhibitors

Marcus Liebermann, Daniela Hoeller, PhD, Susanne Badura, Tamara Tesanovic, Hubert Serve, MD, Martin Ruthardt, MD, Oliver G. Ottmann, MD

Blood (2010) 116 (21): 3236.

https://doi.org/10.1182/blood.V116.21.3236.3236

Published: 2010

Journal Articles

Oligomerization Inhibition Combined with Allosteric Inhibition Abrogates the Transformation Potential of T315I-Positive BCR/ABL.

Afsar Ali Mian, Claudia Oancea, Zihan Zhao, Hubert Serve, MD, PhD, Ottmann Oliver, Martin Ruthardt, MD

Blood (2009) 114 (22): 2964.

https://doi.org/10.1182/blood.V114.22.2964.2964

Published: 2009

Journal Articles

AF4-MLL Expression Is Necessary and Sufficient for Leukemia Onset in Mice

Adelheid Bursen, PhD, Karen Schwabe, Brigitte Rüster, PhD, Anne Wenger, PhD, Martin Ruthardt, MD, Reinhard Henschler, MD, Theo Dingermann, PhD, Rolf Marschalek, PhD

Blood (2008) 112 (11): 685.

https://doi.org/10.1182/blood.V112.11.685.685

Published: 2008

Journal Articles

The Small GTPase Rap1A Is Central for Migration and Adhesion of Mesenchymal Stromal Cells (MSCs)

Erika Deak, Brigitte Ruester, Stephan Göttig, Elena Puccetti, Ph.D., Martin Ruthardt, MD, Erhard Seifried, MD, PhD, Jürgen Scheele, MD, Reinhard Henschler

Blood (2008) 112 (11): 2426.

https://doi.org/10.1182/blood.V112.11.2426.2426

Published: 2008

Journal Articles

Sulindac Sulfide Reverts the Activation of the WNT-Signaling and Aberrant Self Renewal Induced by the AML-Associated Fusion Proteins PML/RARα and PLZF/RARα.

Gunnar Steinert, Anita Seshire, PhD, Dieter Hoelzer, MD, PhD, Martin Ruthardt, MD, Elena Puccetti, PhD

Blood (2007) 110 (11): 878.

https://doi.org/10.1182/blood.V110.11.878.878

Published: 2007

Journal Articles

The t(6;9) Associated DEK/CAN Fusion Protein Does Not Block Differentiation of Early Hematopoietic Stem Cells but Increases Their Stem Cell Capacity.

Claudia Oancea, PhD, Elena Puccetti, PhD, Reinhard Henschler, PhD, Martin Ruthardt, MD, Gesine Bug, MD

Blood (2007) 110 (11): 882.

https://doi.org/10.1182/blood.V110.11.882.882

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

A Network of Activated Cancer Signaling Pathways in a High Risk Subgroup of Acute Myeloid Leukemia Targetable By SRC-Kinase Inhibitors

Transphosphorylation of Endogenous BCR Mediates the Effect of T315I on the Transformation Potential of BCR/ABL

Mechanisms of Antileukemic Activity of the Multikinase Inhibitors Dasatinib and Ponatinib in Acute Lymphoblastic Leukemia (ALL) Harboring the E2A-PBX1 Fusion Gene

The GSK3β-Phosphorylation Sites in the DEK-Portion Are Indispensable for the Leukemogenic Potential of the DEK/CAN Fusion Protein in t(6;9)-Positive Acute Myeloid Leukemia

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome Positive Acute Lymphatic Leukemia

PF-114, a Novel Selective Pan BCR/ABL Inhibitor Targets The T315I and Suppress Models Of Advanced Ph+ ALL

The Reciprocal t(9;22) p96 ABL/BCR fusion Protein Eenhances the Transformation Potential of BCR/ABL and Increases Therapy Resistance in Models of Ph+ Acute Lymphatic Leukemia

The Activation of STAT3 and 5 in t(6;9)(DEK/CAN)-Positive Acute Myeloid Leukemia Models Is Inhibited by Exposure to Arsenic Trioxide

T(6;9)-DEK/CAN-Positive Leukemia: Role of FLT3-ITD for the Determination of the Leukemic Phenotype

Enzymatically Inactive 5-Lipoxygenase Inhibits Wnt-Signaling Activation Induced by Leukemia Inducing Oncogenes.

Modulation of Leukemic Stem Cell Self-Renewal and Cell Fate Decisions by Inhibition of Hedgehog Signalling in Human Acute Lymphoblastic Leukemia (ALL).

Prominin-1/CD133 Is Involved in the Lineage Decision As Well As a in the Sensitivity to Molecular Therapy in Ph+ Acute Lymphatic Leukemia.

Differential Suppressive Effects of Selective PI3K and mTOR and Dual PI3K/mTORC1/C2 Inhibition on Long-Term Cultured Primary Human Acute Lymphoblastic Leukemia (ALL) Cells Implicate a Distinct Role of mTORC2.

The Protein Tyrosine Phosphatase STS-1 Interacts with Bcr-Abl and Impairs the Response of Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) to Tyrosine Kinase Inhibitors

Oligomerization Inhibition Combined with Allosteric Inhibition Abrogates the Transformation Potential of T315I-Positive BCR/ABL.

AF4-MLL Expression Is Necessary and Sufficient for Leukemia Onset in Mice

The Small GTPase Rap1A Is Central for Migration and Adhesion of Mesenchymal Stromal Cells (MSCs)

Sulindac Sulfide Reverts the Activation of the WNT-Signaling and Aberrant Self Renewal Induced by the AML-Associated Fusion Proteins PML/RARα and PLZF/RARα.

The t(6;9) Associated DEK/CAN Fusion Protein Does Not Block Differentiation of Early Hematopoietic Stem Cells but Increases Their Stem Cell Capacity.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only